US2010330074A1PendingUtilityA1
Use of saccharides cross-reactive with bacillus anthracis spore glycoprotein as a vaccine against anthrax
Est. expiryFeb 19, 2028(~1.6 yrs left)· nominal 20-yr term from priority
Inventors:Joanna Kubler-KielbEvguenii VinogradovRachel SchneersonHaijing HuStephen H. LepplaJohn B. Robbins
A61K 39/0208A61K 2039/6081A61K 2039/521C07H 5/04A61K 47/643A61K 39/104A61K 39/07C07H 3/06A61P 31/04A61K 47/646A61K 39/00
66
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Provided are immunogenic compositions and methods for eliciting an immune response against B. anthracis and other bacteria that contain 3-methyl-3-hydroxybutyrate- or 3-hydroxybutyrate-substituted saccharides. Conjugates of 3-methyl-3-hydroxybutyrate- or 3-hydroxybutyrate-substituted saccharides elicit an effective immune response against B. anthracis spores in mammalian hosts to which the conjugates are administered.
Claims
exact text as granted — not AI-modified1 . A pharmaceutical composition comprising at least one immunogenic agent that is cross-reactive with B. anthracis, wherein the immunogenic agent is selected from:
(a) at least one compound comprising:
(b) an isolated B. anthracis antigenic component from Shewanella or P. syringae;
(c) killed whole cells of Shewanella or P. syringae; or
(d) any combination or mixture of (a)-(c).
2 . The pharmaceutical composition of claim 1 , wherein the immunogenic agent is the compound of (a), and the compound of (a) is covalently linked to a polymeric carrier.
3 . The pharmaceutical composition of claim 2 , wherein the polymeric carrier is a protein.
4 . The pharmaceutical composition of claim 1 , wherein the immunogenic agent is an isolated B. anthracis antigenic component from Shewanella, and the component is an isolated capsule from Shewanella spp. MR-4.
5 . The pharmaceutical composition of claim 1 , wherein the immunogenic agent is an isolated B. anthracis antigenic component from P. syringae, and the component is isolated fimbriae from P. syringae.
6 . The pharmaceutical composition of claim 1 , wherein the immunogenic agent is killed whole cells of Shewanella spp. MR-4.
7 . The pharmaceutical composition of claim 1 , wherein the immunogenic agent is killed whole cells of P. syringae.
8 . A pharmaceutical composition comprising at least one compound that is cross-reactive with B. anthracis. wherein the compound comprises
and at least one pharmaceutically acceptable additive.
9 . The pharmaceutical composition of claim 8 , wherein the compound is covalently linked to a polymeric carrier.
10 . The pharmaceutical composition of claim 9 , wherein the polymeric carrier is a pharmaceutically acceptable protein.
11 . The pharmaceutical composition of claim 9 , wherein the compound is covalently linked to a carrier selected from bovine serum albumin, recombinant B. anthracis protective antigen, recombinant P. aeruginosa exotoxin A, tetanus toxoid, diphtheria toxoid, pertussis toxoid, C. perfringens toxoid, hepatitis B surface antigen, hepatitis B core antigen, keyhole limpet hemocyanin, or horseshoe crab hemocyanin.
12 . The pharmaceutical composition of claim 8 , wherein the additive is an adjuvant.
13 . The pharmaceutical composition of claim 8 , wherein the additive is a pharmaceutically acceptable carrier.
14 . The pharmaceutical composition of claim 8 , wherein the compound comprises a polysaccharide isolated from a microorganism that is cross-reactive with B. anthracis.
15 . The pharmaceutical composition of claim 14 , wherein the microorganism is Shewanella or P. syringae.
16 . The pharmaceutical composition of claim 14 , wherein the microorganism is Shewanella spp. MR-4.
17 . An antibody that is immuno-reactive to a compound comprising
wherein the antibody is also immuno-reactive to B. anthracis spores.
18 . The antibody of claim 17 , wherein the antibody is a monoclonal antibody.
19 . A pharmaceutical composition comprising the antibody of claim 17 and a pharmaceutically acceptable carrier.
20 . A vaccine comprising at least one immunogenic agent that is cross-reactive with B. anthracis, wherein the immunogenic agent is selected from:
(a) at least one compound comprising:
(b) an isolated B. anthracis antigenic component from Shewanella or P. syringae;
(c) killed whole cells of Shewanella or P. syringae; or
(d) any combination or mixture of (a)-(c).
21 . The vaccine of claim 20 , wherein the immunogenic agent is the compound of (a), and the compound of (a) is covalently linked to a polymeric carrier.
22 . The vaccine of claim 21 , wherein the polymeric carrier is a protein.
23 . The vaccine of claim 20 , wherein the immunogenic agent is an isolated B. anthracis antigenic component from Shewanella, and the component is an isolated capsule from Shewanella spp. MR-4.
24 . The vaccine of claim 20 , wherein the immunogenic agent is an isolated B. anthracis antigenic component from P. syringae, and the component is isolated fimbriae from P. syringae.
25 . The vaccine of claim 20 , wherein the immunogenic agent is killed whole cells of Shewanella spp. MR-4.
26 . The vaccine of claim 20 , wherein the immunogenic agent is killed whole cells of P. syringae.
27 . An immunogenic conjugate comprising at least one moiety selected from:
covalently linked to a carrier, wherein the conjugate elicits an immune response in a subject.
28 . The conjugate of claim 27 , wherein the moiety is covalently liked to the carrier via the carboxyl group of the —NHCOCH 3 substituent in the first or second moiety, or via the carboxyl group of the —OCH 2 CH(NH 2 )COOH substituent in the third moiety.
29 . The conjugate of claim 28 , wherein the carrier is selected from bovine serum albumin, recombinant B. anthracis protective antigen, recombinant P. aeruginosa exotoxin A, tetanus toxoid, diphtheria toxoid, pertussis toxoid, C. perfringens toxoid, hepatitis B surface antigen, hepatitis B core antigen, keyhole limpet hemocyanin, or horseshoe crab hemocyanin.
30 . A method of inhibiting a Bacillus infection in a subject, the method comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 1 .
31 . The method of claim 30 , wherein the Bacillus is B. anthracis.
32 . The method of claim 30 , wherein the immunogenic agent is killed whole cells of Shewanella or P. syringae, and the killed whole cells are administered to a non-human animal that has been, or may have been, exposed to B. anthracis.
33 . The method of claim 30 , wherein the subject has been, or may have been, exposed to B. anthracis.
34 . The method of claim 30 , wherein the compound is covalently linked to a polymeric carrier.
35 . A method of inhibiting a Bacillus infection in a subject, the method comprising administering to the subject a therapeutically effective amount of the vaccine of claim 20 .
36 . A method of inhibiting a Bacillus infection in a subject, the method comprising administering to the subject a therapeutically effective amount of the immunogenic conjugate of claim 27 .
37 . A method for stimulating an immune response in a subject against B. anthracis, comprising
selecting a subject in need of stimulating an immune response against B. anthracis; and administering to the subject at least one immunogenic agent selected from: (a) at least one compound comprising:
(b) an isolated B. anthracis antigenic component from Shewanella or P. syringae;
(c) killed whole cells of Shewanella or P. syringae; or
(d) any combination or mixture of (a)-(c).
38 . The method of claim 37 , wherein the immunogenic agent is the compound of (a), and the compound of (a) is covalently linked to a polymeric carrier.
39 . The method of claim 38 , wherein the polymeric carrier is a protein.
40 . The method of claim 37 , wherein the immunogenic agent is an isolated B. anthracis antigenic component from Shewanella, and the component is an isolated capsule from Shewanella spp. MR-4.
41 . The method of claim 37 , wherein the immunogenic agent is an isolated B. anthracis antigenic component from P. syringae, and the component is isolated fimbriae from P. syringae.
42 . The method of claim 37 , wherein the immunogenic agent is killed whole cells of Shewanella spp. MR-4.
43 . The pharmaceutical composition of claim 37 , wherein the immunogenic agent is killed whole cells of P. syringae.
44 . A method for screening compounds against B. anthracis spores, the method comprising
providing a compound comprising
adding an antibody that is immuno-reactive with a B. anthracis spore,
determining a level of reactivity of the compound with the antibody.
45 . The method of claim 44 , wherein the level of reactivity is determined by ELISA.Join the waitlist — get patent alerts
Track US2010330074A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.